This 2026 guideline provides an integrated framework for managing cardiovascular, kidney, and metabolic health together, rather than treating these conditions separately. It introduces a structured approach to CKM staging and risk assessment, including the use of PREVENT cardiovascular risk equations and CKM risk-enhancing factors. The guideline provides recommendations covering metabolic risk factors, obesity, diabetes, chronic kidney disease, cardiovascular disease, and heart failure, with emphasis on therapies that provide both cardiovascular and kidney benefits. It was developed through systematic evidence review and is intended as a resource for clinical and public-health professionals.